Published in Mediators Inflamm on January 01, 2006
Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications. AAPS J (2014) 0.87
Lipid disturbances in psoriasis: an update. Mediators Inflamm (2010) 0.77
Study on Certain Biomarkers of Inflammation in Psoriasis Through "OMICS" Platforms. Open Biochem J (2014) 0.76
Ultraviolet B Inhibits IL-17A/TNF-α-Stimulated Activation of Human Dermal Fibroblasts by Decreasing the Expression of IL-17RA and IL-17RC on Fibroblasts. Front Immunol (2017) 0.75
Psoriasis. N Engl J Med (2005) 8.56
Severe psoriasis--oral therapy with a new retinoid. Dermatologica (1978) 5.67
Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol (2001) 3.08
Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A (1989) 2.87
T-cell subpopulations in the blood and skin of patients with psoriasis. Br J Dermatol (1984) 2.54
Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol (1997) 2.47
Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol (1991) 2.24
The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology (2005) 1.99
Objective assessment of compliance with psoriasis treatment. Arch Dermatol (2004) 1.46
Cytokines in skin lesions of psoriasis. Cytokine (1990) 1.34
Elevated levels of interleukin 2 receptor in sera of patients with atopic dermatitis and psoriasis. Br J Dermatol (1988) 1.21
Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents (1998) 1.21
Interleukin 2 and psoriasis. Arch Dermatol (1988) 1.14
Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients--relationships with disease severity. Clin Exp Dermatol (1994) 1.12
Cytokines in psoriasis. Int J Dermatol (1999) 1.12
Increased IL-6 production by monocytes and keratinocytes in patients with psoriasis. J Invest Dermatol (1991) 1.10
Insights into the role of fibroblasts in human autoimmune diseases. Clin Exp Immunol (2005) 1.10
Interleukin-6 in normal skin and psoriasis. Acta Derm Venereol (1992) 1.09
Interleukin-1 and interleukin-6 in psoriasis. J Invest Dermatol (1990) 1.06
Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol (2004) 0.99
Immunohistochemical analysis of keratinocyte growth factor and fibroblast growth factor 10 expression in psoriasis. Exp Dermatol (2005) 0.99
Neutrophil functions and IL-8 in psoriatic arthritis and in cutaneous psoriasis. Inflammation (1998) 0.93
Serum levels of proinflammatory cytokines in psoriasis patients from Saudi Arabia. Int J Dermatol (2005) 0.93
Detection of inflammatory cytokines in psoriatic skin. Arch Dermatol Res (1995) 0.92
Inverse regulation of the nuclear factor-kappaB binding to the p53 and interleukin-8 kappaB response elements in lesional psoriatic skin. J Invest Dermatol (2005) 0.90
Interleukin-6: a cytokine with potential diagnostic and therapeutic roles. J Lab Clin Med (1994) 0.89
Serum-soluble interleukin 2 receptor in psoriasis. Failure to reflect clinical improvement. Acta Derm Venereol (1990) 0.87
In situ expression of messenger RNA of interleukin-1 and interleukin-6 in psoriasis: interleukin-6 involved in formation of psoriatic lesions. Arch Dermatol Res (1991) 0.86
Immunological mechanisms involved in psoriasis. Springer Semin Immunopathol (1992) 0.84
Interleukin-6 in psoriasis: expression and mitogenicity studies. Arch Dermatol Res (1992) 0.83
Cytokine-stimulated human dermal microvascular endothelial cells produce interleukin 6--inhibition by hydrocortisone, dexamethasone, and calcitriol. J Invest Dermatol (1992) 0.82
Plasma concentrations of IFN-gamma and TNF-alpha in psoriatic patients before and after local treatment with dithranol ointment. J Eur Acad Dermatol Venereol (1998) 0.82
Interleukin-6 and tumour necrosis factor levels decrease in the suction blister fluids of psoriatic patients during effective therapy. Dermatology (1994) 0.82
IL-1 alpha, IL-1 beta and psoriasis: conflicting results in the literature. Opposite behaviour of the two cytokines in lesional or non-lesional extracts of whole skin. J Biol Regul Homeost Agents (1998) 0.81
Interleukin-6 in the epidermis of patients with psoriasis before and during PUVA treatment. Acta Derm Venereol (1989) 0.81
Expression of cytokines and their receptors by psoriatic fibroblast. I. Altered IL-6 synthesis. Cytokine (1996) 0.81
Serum interleukin-6 levels as an early marker of therapeutic response to UVB radiation and topical steroids in psoriatic patients. Int J Clin Lab Res (1994) 0.79
[The role of cytokines for the pathogenesis of psoriasis]. Hautarzt (1993) 0.78
A new era in the management of psoriasis? Promises and facts. Dermatology (2005) 0.77
Effect of UVB plus tar therapy on serum levels of interleukin-2 receptors in patients with psoriasis. Clin Exp Dermatol (1991) 0.77
Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-alpha, but not IL-1. Br J Dermatol (1997) 0.77
sICAM-1, sIL-2R and beta 2-microglobulin serum levels in patients affected with psoriasis: relationship with disease severity. Arch Dermatol Res (1994) 0.77
Aspects of interleukin-8 gene expression by gingival and dermal fibroblasts stimulated with interleukin-1beta or tumour necrosis factor alpha. J Int Acad Periodontol (2004) 0.76
Lipopolysaccharide-activated CD4+CD25+ T regulatory cells inhibit neutrophil function and promote their apoptosis and death. J Immunol (2006) 1.49
Lupus vulgaris: report of two cases. Int J Dermatol (2005) 1.19
The effect of chronic ultraviolet radiation on the human immune system. Photochem Photobiol (2008) 1.19
Environmental risk factors predisposing to the development of basal cell carcinoma. Dermatol Surg (2004) 1.11
Predominance of Type 1 cytokines and decreased number of CD4(+)CD25(+high) T regulatory cells in peripheral blood of patients with recurrent aphthous ulcerations. Immunol Lett (2005) 1.08
1-Methylnicotinamide: a potent anti-inflammatory agent of vitamin origin. Pol J Pharmacol (2003) 1.07
The number and distribution of blood dendritic cells in the epidermis and dermis of healthy human subjects. Folia Histochem Cytobiol (2006) 1.03
Involvement of nitric oxide donor compounds in the bactericidal activity of human neutrophils in vitro. J Med Microbiol (2003) 0.96
Cytokine secretion by decidual lymphocytes in transient hypertension of pregnancy and pre-eclampsia. Mediators Inflamm (2002) 0.95
Dermatitis artefacta in a patient with paranoid syndrome. Acta Dermatovenerol Alp Pannonica Adriat (2007) 0.93
Cytokines locally produced by lymphocytes removed from the hypertrophic nasopharyngeal and palatine tonsils. Int J Pediatr Otorhinolaryngol (2005) 0.91
Relationship between peripheral blood dendritic cells and cytokines involved in the pathogenesis of systemic lupus erythematosus. Eur Cytokine Netw (2004) 0.91
Combined occurrence of filaggrin mutations and IL-10 or IL-13 polymorphisms predisposes to atopic dermatitis. Exp Dermatol (2011) 0.90
Heart rate and arrhythmia in patients with psoriasis vulgaris. Arch Med Res (2006) 0.90
Quality of life and satisfaction with life in SLE patients-the importance of clinical manifestations. Clin Rheumatol (2010) 0.90
The distribution of peripheral blood dendritic cells assayed by a new panel of anti-BDCA monoclonal antibodies in healthy representatives of the polish population. Cell Mol Biol Lett (2004) 0.89
Lymphocyte subset distribution and cytokine secretion in third trimester decidua in normal pregnancy and preeclampsia. Eur J Obstet Gynecol Reprod Biol (2003) 0.89
Epidermal growth factor enhances TNF-alpha-induced priming of human neutrophils. Immunol Lett (2005) 0.88
Persistent improvement of previously recalcitrant Hailey-Hailey disease with electron beam radiotherapy. Acta Derm Venereol (2010) 0.88
Allergic diseases, drug adverse reactions and total immunoglobulin E levels in lupus erythematosus patients. Mediators Inflamm (2003) 0.87
Acetylation genotype and phenotype in patients with systemic lupus erythematosus. Pharmacol Rep (2006) 0.86
Does the KIR2DS5 gene protect from some human diseases? PLoS One (2010) 0.86
Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients. Mediators Inflamm (2005) 0.85
Effective treatment of nodular amyloidosis with carbon dioxide laser. J Cutan Med Surg (2012) 0.85
An enhanced risk of basal cell carcinoma is associated with particular polymorphisms in the VDR and MTHFR genes. Exp Dermatol (2011) 0.85
Circulating pemphigus autoantibodies in healthy relatives of pemphigus patients: coincidental phenomenon with a risk of disease development? Arch Dermatol Res (2007) 0.85
[Medical and legal aspects of smoking]. Pol Merkur Lekarski (2012) 0.84
Antioxidant effect of hyaluronan on polymorphonuclear leukocyte-derived reactive oxygen species is dependent on its molecular weight and concentration and mainly involves the extracellular space. Postepy Hig Med Dosw (Online) (2009) 0.84
Protective effect of the KIR2DS1 gene in atopic dermatitis. Gene (2013) 0.84
[Effect of high doses of shark liver oil supplementation on T cell polarization and peripheral blood polymorphonuclear cell function]. Pol Merkur Lekarski (2005) 0.83
Dysfunction of CD4+CD25high T regulatory cells in patients with recurrent aphthous stomatitis. J Oral Pathol Med (2008) 0.83
Proinflammatory interferon-gamma--inducing monokines (interleukin-12, interleukin-18, interleukin-15)--serum profile in patients with systemic lupus erythematosus. Eur Cytokine Netw (2002) 0.83
Circulating proangiogenic molecules PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus. Eur Cytokine Netw (2007) 0.83
Innate immune system is implicated in recurrent aphthous ulcer pathogenesis. J Oral Pathol Med (2003) 0.83
[Quality of life predictors among patients suffering from systemic lupus erythematosus]. Przegl Lek (2006) 0.82
Glycation endproducts, soluble receptor for advanced glycation endproducts and cytokines in diabetic and non-diabetic pregnancies. Am J Reprod Immunol (2009) 0.82
Vitamin D serum level changes in psoriatic patients treated with narrowband ultraviolet B phototherapy are related to the season of the irradiation. Photodermatol Photoimmunol Photomed (2011) 0.82
[Hyaluronan-mediated regulation of inflammation]. Postepy Hig Med Dosw (Online) (2007) 0.82
[Prevalence of autoantibodies directed against 1,25(OH)2D3 in patients with systemic lupus erythematosus]. Pol Merkur Lekarski (2010) 0.81
Immunotherapy of patients with recurrent spontaneous miscarriage and idiopathic infertility: does the immunization-dependent Th2 cytokine overbalance really matter? Arch Immunol Ther Exp (Warsz) (2012) 0.81
Reactive oxygen intermediates and serum antioxidative system in patients with chronic C hepatitis treated with IFN-alpha and thymus factor X. Arch Immunol Ther Exp (Warsz) (2006) 0.81
The dynamism of cutaneous lupus erythematosus: mild discoid lupus erythematosus evolving into SLE with SCLE and treatment-resistant lupus panniculitis. Clin Rheumatol (2006) 0.81
Serum concentration of interleukin-6 is increased both in active and remission stages of pemphigus vulgaris. Mediators Inflamm (2008) 0.81
Repeated suberythemal UVB preexposure protects against high-dose UVB-induced expression of vitamin D receptor protein in human Skin. J Invest Dermatol (2011) 0.80
[Neurological disorders in systemic lupus erythematosus patients]. Pol Merkur Lekarski (2009) 0.80
Pathogenic activity of circulating anti-desmoglein-3 autoantibodies isolated from pemphigus vulgaris patients. Arch Med Sci (2012) 0.80
Risk factors in Central Poland for the development of superficial and nodular basal cell carcinomas. Arch Med Sci (2010) 0.80
IL-17 expression in dermatitis herpetiformis and bullous pemphigoid. Mediators Inflamm (2013) 0.80
[Concentration of selected cytokines in serum of patients with acne rosacea]. Przegl Lek (2008) 0.80
Peripheral blood lymphocyte apoptosis and circulating dendritic cells in patients with systemic lupus erythematosus: correlation with immunological status and disease-related symptoms. Clin Rheumatol (2006) 0.80
HLA-C C1C2 heterozygosity may protect women bearing the killer immunoglobulin-like receptor AA genotype from spontaneous abortion. J Reprod Immunol (2010) 0.79
Interleukin 4 plasma levels in psoriasis vulgaris patients. Med Sci Monit (2004) 0.79
Correlations between concentrations of interleukin (IL)-17A, IL-17B and IL-17F, and endothelial cells and proangiogenic cytokines in systemic lupus erythematosus patients. Eur Cytokine Netw (2013) 0.79
[CD4+CD25+ T regulatory cells: their physiology and role in modulating immune response]. Postepy Hig Med Dosw (Online) (2005) 0.79
The imbalance between metalloproteinases and their tissue inhibitors is involved in the pathogenesis of dermatitis herpetiformis. Mediators Inflamm (2005) 0.79
Prognostic value of the immunological phenomena and relationship with clinicopathological characteristics of the tumor--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ lymphocytes in squamous cell laryngeal carcinoma. Part II. Folia Histochem Cytobiol (2011) 0.79
[Modification of innate immunity in humans by active components of shark liver oil]. Pol Merkur Lekarski (2002) 0.78
Influence of systemic photochemotherapy on regulatory T cells and selected cytokine production in psoriatic patients: a pilot study. Med Sci Monit (2005) 0.78
[Biological action and clinical application of shark liver oil]. Pol Merkur Lekarski (2006) 0.78
Plaque form of warty dyskeratoma - acantholytic dyskeratotic acanthoma. J Cutan Pathol (2007) 0.78
Influence of opioid peptides on human neutrophil apoptosis and activation in vitro. Mediators Inflamm (2002) 0.78
The role of tumor cells in the modification of T lymphocytes activity--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ cells in squamous cell laryngeal carcinoma. Part I. Folia Histochem Cytobiol (2011) 0.78
Flow cytometric evaluation of human neutrophil apoptosis during nitric oxide generation in vitro: the role of exogenous antioxidants. Mediators Inflamm (2005) 0.78
Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum level in psoriatic patients. Arch Dermatol Res (2012) 0.78
Repeated doses of UVR cause minor alteration in cytokine serum levels in humans. Mediators Inflamm (2005) 0.78
Photoprovocation in cutaneous lupus erythematosus: a multicenter study evaluating a standardized protocol. J Invest Dermatol (2011) 0.78
Disturbances of the expression of metalloproteinases and their tissue inhibitors cause destruction of the basement membrane in pemphigoid. Pol J Pathol (2006) 0.77
Effect of exogenous opioid peptides on TNF-alpha-induced human neutrophil apoptosis in vitro. Arch Immunol Ther Exp (Warsz) (2003) 0.77
Increased cyclooxygenase expression and thymine dimer formation after repeated exposures of humans to low doses of solar simulated radiation. Exp Dermatol (2007) 0.77
Lack of effect of repeated suberythemal ultraviolet-B exposures on human blood dendritic subtypes. Photodermatol Photoimmunol Photomed (2005) 0.77
Merkel cell carcinoma in a kidney transplant patient: Case report and update on management. Ann Transplant (2010) 0.77
Profile of peripheral blood neutrophil cytokines in diabetes type 1 pregnant women and its correlation with selected parameters in the newborns. Am J Reprod Immunol (2009) 0.77
Early cardiovascular involvement in patients with systemic sclerosis (SSc). Med Sci Monit (2002) 0.77
c-Jun N-terminal kinase is involved in mercuric ions-mediated interleukin-4 secretion in mast cells. Int Arch Allergy Immunol (2005) 0.77
Serum levels of tissue inhibitor of metalloproteinases 2 in systemic sclerosis: a preliminary study. Med Sci Monit (2002) 0.77
Expression of selected ADAMs in bullous pemphigoid and dermatitis herpetiformis. J Dermatol Sci (2009) 0.77
[Drug eruptions]. Przegl Lek (2002) 0.77
[Serum total antioxidative capacity in patients with essential hypertension]. Pol Merkur Lekarski (2004) 0.77
[Scleroderma-like lesions in the course of autoimmune hepatitis. Case report]. Przegl Lek (2005) 0.77
[CD4+CD25+ T regulatory cells in pathophysiology and therapy of immunologic diseases]. Postepy Hig Med Dosw (Online) (2005) 0.76
[Evaluation of applicability of HE4 and ROMA in the preoperative diagnosis of adnexal masses]. Ginekol Pol (2015) 0.76
Detection of pemphigus autoantibodies by IIF and ELISA tests in patients with pemphigus vulgaris and foliaceus and in healthy relatives. Med Sci Monit (2003) 0.76
The effect of repeated exposures to low-dose UV radiation on the apoptosis of peripheral blood mononuclear cells. Arch Dermatol (2009) 0.76
Expression of selected adhesion molecules in dermatitis herpetiformis and bullous pemphigoid. Pol J Pathol (2009) 0.76